Groundbreaking New Melanoma Treatment Shows 49% Improvement in Survival Rates: Innovative Vaccine-Drug Combo Offers Hope in Recent Trial
Moderna Inc., the creator of the innovative melanoma vaccine, revealed that individuals grappling with advanced melanomas exhibited a 49% lower likelihood of mortality or cancer recurrence within three years when administered the vaccine in conjunction with Merck’s cancer drug Keytruda, compared to those receiving Keytruda alone. A new melanoma treatment has demonstrated remarkable efficacy in … Read more